usdaed

Now, a sale of this size isn’t necessarily cause for alarm. It was, in fact, the largest of two recent sales by Mr. Hanna, exceeding a prior transaction of 10,156 shares. The average sale size for insiders has been around 14,818 shares, so it’s a bit above that, but not wildly so. It reduced his direct holdings by a modest 3.16%, leaving him still with a substantial stake in the company. It’s like selling off a few extra bricks from a very large house – the house remains standing, and the owner is still very much in residence.

On the surface, things looked…fine. Revenue up 17% to $81.3 billion. Operating income soaring. An operating margin of 47%? Someone’s doing something right. Azure, their cloud division (where all the AI magic happens), was up 39%. So, numbers were good. Very good, even. But investors? They’re a fickle bunch. Like exes at a wedding.

The great tech constellations experienced a momentary eclipse. Microsoft (MSFT +0.37%), a titan of our age, lost ground—nearly ten percent, a sum equivalent to the fortunes of smaller kingdoms—falling to $433.50. A loss of that magnitude is not merely a number, but a tremor felt through the very foundations of the digital world. The market, it seems, is learning that even the most seemingly boundless growth has its limits. Meta Platforms (META 2.03%), however, shone with a different light, its earnings a counterpoint to the prevailing gloom, cushioning the fall, a momentary reprieve.

The FDA, an institution as ancient and inscrutable as the mountains themselves, has adjusted its timetable. The decision on orforglipron, initially slated for March, now drifts towards April, a delay of barely two weeks, yet enough to stir the anxieties of investors. It’s a minor postponement, they say, aligning with similar shifts for other pharmaceutical candidates. But in the world of biotechnology, where months can feel like lifetimes, and fortunes are built and undone on the basis of weeks, even a small delay can feel like an eternity. The air itself seems to thicken with uncertainty, like the prelude to a summer storm.

The reduction in Mr. Novack’s stake, whilst substantial in absolute terms, represents a mere 0.05% of the company’s outstanding shares as of January 24th, 2026. One might observe that such a disposition, whilst not inconsiderable, does not entirely dismantle his connection to Dynavax, leaving him with a position that, while diminished, still allows for a vested interest in its future prospects.

One seeks, naturally, to mitigate. To construct a bulwark against the coming…adjustment. The standard instruments – the broad indices – offer a comfort that feels increasingly illusory. Decades, they suggest, are required for recovery. A timescale that feels less like investment strategy and more like a sentence. One is left to wonder if the ‘recovery’ is merely a return to the starting point, a perpetual loop disguised as progress.

The week commenced with a flourish of patriotic expenditure, as USA Rare Earth secured a substantial injection of federal funding – $277 million, to be precise – and a further $1.3 billion in loans under the CHIPS Act, augmented by a generous $1.5 billion in private capital. A commendable display of faith, one might say, though whether it will actually result in anything beyond a proliferation of press releases remains to be seen. It does, however, offer a degree of de-risking, which is always appreciated by shareholders, and a bolstering of domestic supply, which is, of course, the official narrative.

The last twelve months haven’t been kind to either of them. Bitcoin took a hit, sure. But XRP? Down over forty percent. A steeper fall. The kind that makes a man check his assumptions, and his portfolio. It dipped below two dollars recently. A price point that felt less like support and more like a warning.

it’s more than double the recent median sell size for this particular insider. This isn’t a gradual trickle; it’s a noticeable adjustment. (One might compare it to rearranging deckchairs on the Titanic, except the Titanic is doing quite well, thank you, and the deckchairs are, in fact, highly sophisticated micro-acoustic microphones.)